Reason: Acquired by CSL
Last recorded trade on: February 23, 2023
Source: https://www.fiercepharma.com/pharma/csl-agrees-to-11-7-billion-deal-to-acquire-vifor-largest-m-a-deal-year
P/E ratio for Vifor Pharma (VIFN.SW)
P/E ratio at the end of 2020: 25.2
According to Vifor Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 28.5384. At the end of 2020 the company had a P/E ratio of 25.2.
P/E ratio history for Vifor Pharma from 2004 to 2020
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2020 | 25.2 | -68.33% |
| 2019 | 79.5 | 56.09% |
| 2018 | 50.9 | 551.18% |
| 2017 | 7.82 | -77.92% |
| 2016 | 35.4 | -7.03% |
| 2015 | 38.1 | 87.69% |
| 2014 | 20.3 | 2.3% |
| 2013 | 19.8 | 40.91% |
| 2012 | 14.1 | -17% |
| 2011 | 17.0 | 0.23% |
| 2010 | 16.9 | 24.45% |
| 2009 | 13.6 | -2.81% |
| 2008 | 14.0 | -54.63% |
| 2007 | 30.8 | 3.84% |
| 2006 | 29.7 | 3.8% |
| 2005 | 28.6 | 4.24% |
| 2004 | 27.4 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.